The Problem
Broad Wnt inhibition is overly toxic
Pharma tried for over 30 years, but broad Wnt inhibition causes dose-limiting toxicity.
The first FZD5 selective inhibitor program
Designed for Wnt inhibition without prohibitive toxicity
Supported by
The Solution
Receptor-selective Wnt inhibition
We develop receptor-selective Wnt inhibitors designed for a wide therapeutic window.
Our pipeline
FZD5 inhibitor
Triple-negative breast cancer and pancreatic cancer
Current stage: Lead optimization
- Discovery (completed)
- Lead optimization (current stage)
- IND-enabling (not started)
- Phase 1 (not started)
- Phase 2 (not started)
Undisclosed FZD inhibitor
Undisclosed indication
Current stage: Discovery
- Discovery (current stage)
- Lead optimization (not started)
- IND-enabling (not started)
- Phase 1 (not started)
- Phase 2 (not started)
The Team
Business veterans and scientists with two decades and 8,000+ citations in Wnt research
Prof. Vladimir Katanaev
Professor
15+ years leading Wnt/Frizzled research. Professor at the University of Geneva and Director of Qatar Biomedical Research Institute and the Translational Oncology Research Center.
Marc Denier
CEO
Background in entrepreneurship, operating and investing. Built Wynveris's scientific, IP, BD, and competitive strategy.
Mathurin Baquié
Co-Founder
Global Medical Customer Manager - International Business Unit - Immunotherapy at Octapharma. Experienced biotech startup founder.
Alexey Koval
Senior scientist
15+ years of expertise in Wnt pathway research. Discovered the receptor-selective compounds from 54,080-compound screen.